The global VR market to grow at a compound annual growth rate of 13% from $7 billion in 2018 to $28 billion in 2030.
Approval based on HIMALAYA Phase III trial results which showed single priming dose of Imjudo added to Imfinzi reduced risk of death by 22% vs. sorafenib
Paliperidone Extended-Release Tablets (RLD Invega) had estimated annual sales of USD 112 million in the U.S. (IQVIA MAT August 2022).
Separate Phase 3 study evaluating 200 days of therapy with PREVYMIS in HSCT recipients at high risk of late clinically significant CMV infection recently completed, meeting its primary endpoint
Paliperidone Extended-Release Tablets (RLD Invega) had estimated annual sales of US $112 million in the US
The award recognizes Parexel for delivering the best decentralized trial experience for customers through its capabilities, expertise, and patient recruitment and retention strategies
The acquisition of these two brands expands Lupin's portfolio of inhalation products in the U.S.
None of the observations are related to data integrity and Alembic Pharmaceuticals management believes that they are addressable
He also highlighted the need for community awareness for continued implementation of the Covid Appropriate Behaviour (CAB) especially in view of the upcoming festival season
He is a seasoned business leader with a successful track record of over 26 years across local and area roles within the pharmaceutical industry
Subscribe To Our Newsletter & Stay Updated
